Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK

References

• Menichetti F, Sganga G. Definition and classification of intra-abdominal infections. J Chemo 2009;21(Suppl1):3–4
   Google Scholar
• Sartelli M, Catena F, Ansaloni L, et al. Complicated intra-abdominal infections in Europe: a comprehensive review of the CIAO study. W J Emerg Surg 2012;7:36
   PubMed Web of Science ®Google Scholar
• Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect 2010;11:79–109
   PubMed Web of Science ®Google Scholar
• Davey PG, Marwick C. Appropriate vs. inappropriate antimicrobial therapy. Clin Microbiol Infect Offic Publ Eur Soc Clin Microbiol Infect Dis 2008;14(Suppl3):15–21
   Web of Science ®Google Scholar
• Falagas ME, Barefoot L, Griffith J, et al. Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections. Eur J Clin Microbiol Infect Dis 1996;15:913–21
   PubMed Web of Science ®Google Scholar
• Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462–74
   PubMed Web of Science ®Google Scholar
• Edelsberg J, Berger A, Schell S, et al. Economic consequences of failure of initial antibiotic therapy in hospitalized adults with complicated intra-abdominal infections. Surg Infect 2008;9:335–47
   PubMed Web of Science ®Google Scholar
• Dalfino L, Bruno F, Colizza S, et al. Cost of care and antibiotic prescribing attitudes for community-acquired complicated intra-abdominal infections in Italy: a retrospective study. W J Emerg Surg 2014;9:39
   PubMed Web of Science ®Google Scholar
• Public Health England. English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) 2010 to 2014. Report 2015. 2015. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/477962/ESPAUR_Report_2015.pdf 9 September 2016
   Google Scholar
• British Society for Antimicrobial Chemotherapy. BSAC Resistance Surveillance Project. 2015. http://www.bsacsurv.org/. [Last accessed 5 May 2017]
   Google Scholar
• Sartelli M, Catena F, Ansaloni L, et al. Complicated intra-abdominal infections worldwide: the definitive data of the CIAOW Study. W J Emerg Surg 2014;9:37
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance surveillance in Europe 2011. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net); Stockholm: ECDC 2012
   Google Scholar
• Eckmann C, Dryden M, Montravers P, et al. Antimicrobial treatment of “complicated” intra-abdominal infections and the new IDSA guidelines? A commentary and an alternative European approach according to clinical definitions. Eur J Med Res 2011;16:115–26
   PubMed Web of Science ®Google Scholar
• Zerbaxa U.S. Prescribing Information. 2016. http://www.merck.com/product/usa/pi_circulars/z/zerbaxa/zerbaxa_pi.pdf. [Last accessed 8 December 2015]
   Google Scholar
• Zosyn® (Piperacillin and Tazobactam for Injection, USP) Prescribing Information. 2017. http://labeling.pfizer.com/showlabeling.aspx?id=416. [Last accessed 5 May 2017]
   Google Scholar
• Office for National Statistics. A1.1 2014-based expectation of life, 1981–2064, principal projection, United Kingdom; 2015. http://www.ons.gov.uk/ons/rel/lifetables/past-and-projected-data-from-the-period-and-cohort-life-tables/2014-based/rft-a1-1.xls 18 February 2016
   Google Scholar
• Sturkenboom MC, Goettsch WG, Picelli G, et al. Inappropriate initial treatment of secondary intra-abdominal infections leads to increased risk of clinical failure and costs. Br J Clin Pharmacol 2005;60:438–43
   PubMed Web of Science ®Google Scholar
• Krobot K, Yin D, Zhang Q, et al. Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 2004;23:682–7
   PubMed Web of Science ®Google Scholar
• Department of Health. NHS reference costs 2013 to 2014. 2015. https://www.gov.uk/government/publications/nhs-reference-costs-2013-to-2014 18 February 2016
   Google Scholar
• Monthly Index of Medical Specialties. 2016. http://www.mims.co.uk/ 18 February 2016
   Google Scholar
• Jansen JP, Kumar R, Carmeli Y. Cost-effectiveness evaluation of ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance. Value Health J Int Soc Pharmacoecon Outcomes Res 2009;12:234–44
   Web of Science ®Google Scholar
• Scottish Medicines Consortium. Guidance to Manufacturers for Completion of New Product Assessment Form (NPAF). October 2014. https://www.scottishmedicines.org.uk/files/submissionprocess/Guidance_on_NPAF_Final_October_2014.doc 18 February 2016
   Google Scholar
• National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. 2013. https://www.nice.org.uk/article/pmg9/chapter/foreword 18 February 2016
   Google Scholar
• Siebert U, Alagoz O, Bayoumi AM, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–3. Value Health J Int Soc Pharmacoecon Outcomes Res 2012;15:812–20
   Web of Science ®Google Scholar
• Marchaim D, Gottesman T, Schwartz O, et al. National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemo 2010;54:5099–104
   PubMed Web of Science ®Google Scholar
• Aloush V, Navon-Venezia S, Seigman-Igra Y, et al. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemo 2006;50:43–8
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Judging whether pubilc health interventions offer value for money. Local government briefing [LGB10]. 2013. https://www.nice.org.uk/advice/lgb10/chapter/judging-the-cost-effectiveness-of-public-health-activities#nices-approach-to-assessing-public-health-interventions 5 May 2017
   Google Scholar
• Zilberberg MD, Mody SH, Chen J, et al. Cost-effectiveness model of empiric doripenem compared with imipenem-cilastatin in ventilator-associated pneumonia. Surg Infect 2010;11:409–17
   PubMed Web of Science ®Google Scholar
• Kauf TL, Medic G, Dryden M, et al. Use of surveillance data to examine the cost-effectiveness of alternative approaches to empiric antibiotic therapy in gram-negative nosocomial pneumonia. Am J Respir Crit Care Med 2015;191:A5443
   Web of Science ®Google Scholar
• Prabhu V, Sen S, Miller B, et al. Using an economic model to choose initial appropriate antibiotic therapy based on differences in in-vitro susceptibility to cftolozane/tazobactam and piperacillin/tazobactam. Value Health J Int Soc Pharmacoecon Outcomes Res 2015;18:A536
   Google Scholar
• Kauf TL, Prabhu VS, Medic G, et al. Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections. BMC Infect Dis 2017;17:314
   PubMed Web of Science ®Google Scholar